Active Cancer NIHR-supported project Brain & Nervous System

A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma

Funder NIHR (part of DHSC)
Recipient organisation NIHR Biomedical Research Centre at the Royal Marsden and the ICR Source-published name: NIHR Royal Marsden Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Feb 2025 — Aug 2028

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Juanita Lopez (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A Phase 1/2 trial of Amivantanab as monotherapy in combination with Temozolomide in patients with high grade malignant brain tumours within the Minderoo 5G platform
OlaPArib and RADIotherapy or olaparib and radiotherapy plus temozolomide in newly-diagnosed Glioblastoma stratified by MGMT status: 2 parallel phase I studies
OlaPArib and RADIotherapy or olaparib and radiotherapy plus temozolomide in newlydiagnosed Glioblastoma stratified by MGMT status: 2 parallel phase I studies
A randomised controlled phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma
A Phase 1/2, Safety Lead-in and, Open -label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab in Previously Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

Original classification

Precision Therapeutics

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.